Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Large-scale testing (Phase 3)Active Not RecruitingNCT02446600
What this trial is testing

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated Carcinoma+10 more
National Cancer Institute (NCI) 579
Early research (Phase 1)Study completedNCT01459380
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Who this might be right for
Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous Carcinoma+5 more
National Cancer Institute (NCI) 41
Early research (Phase 1)Active Not RecruitingNCT02627443
What this trial is testing

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Metastatic Fallopian Tube CarcinomaMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal Carcinoma+9 more
National Cancer Institute (NCI) 35
Large-scale testing (Phase 3)Active Not RecruitingNCT00565851
What this trial is testing

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Clear Cell AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+22 more
National Cancer Institute (NCI) 1,052
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Testing effectiveness (Phase 2)Ended earlyNCT04814875
What this trial is testing

Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma+1 more
THERAPIM PTY LTD 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07504588
What this trial is testing

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Who this might be right for
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 54
Early research (Phase 1)Study completedNCT00002600
What this trial is testing

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23
87